Thus, the glycolysis inhibitor 2-DG can attenuate the anti-apoptotic effects of survivin and decrease tumor cell proliferation, making the tumor sensitive to chemotherapeutic agents (96, 97). This evidence concerns the gene BIRC5 and neoplasm.